The bispecific antibody Ivanesimab binds to the VEGF dimer, creating a "daisy chain" of antibody-VEGF complexes. This multimerization concentrates the drug in the tumor microenvironment, where VEGF is high, and enhances its ability to bind and block PD-1 more effectively than single-molecule approaches.

The rationale for developing Sigvotatug Vedotin extends beyond its direct cytotoxic effect. Preclinical data shows that blocking the IB6 pathway can increase the potency of PD-1/PD-L1 checkpoint inhibitors, suggesting a powerful synergistic effect that could lead to highly effective future combination therapies.

Previously underperforming cancer targets like TIGIT and LAG-3 are seeing renewed interest. Innovative antibody engineering, such as creating bispecific antibodies that target multiple pathways simultaneously, is giving these 'failed' targets new life and potential for clinical success.

A therapeutic approach called "T-cell engagers" or "BiTEs" uses engineered antibodies with two different heads. One side binds to a cancer cell, while the other binds to a nearby T-cell. This effectively brings the killer cell and the target together, leveraging the body's existing immune cells without genetic modification.

An innovative strategy for solid tumors involves using bispecific T-cell engagers to target the tumor stroma—the protective fibrotic tissue surrounding the tumor. This novel approach aims to first eliminate this physical barrier, making the cancer cells themselves more vulnerable to subsequent immune attack.

T-cells have natural inhibitory signals, or "brakes" (like PD-1), to prevent over-activation. Some cancers exploit this. Checkpoint inhibitor drugs block these brakes, unleashing a patient's existing T-cells to attack cancer cells more aggressively. This approach has been miraculous for cancers like melanoma.

After standard immunotherapy biomarkers like PD-L1 and TMB proved ineffective in SCLC, the field shifted to a more direct approach. Novel therapies like the bispecific antibody tarlatumab target surface proteins such as DLL3, physically bridging immune cells to cancer cells without relying on predictive biomarkers.

Unlike bevacizumab's long 20-day half-life and associated bleeding risks that excluded squamous cell carcinoma patients, new bispecifics have a ~6-day half-life. This results in a similar but less severe toxicity profile, broadening their clinical application to a wider patient population.

The bispecific antibody Pumitamig demonstrated identical overall response rates in both PD-L1 positive and negative triple-negative breast cancer patients. This is significant as it provides a potential immunotherapy option for the two-thirds of patients who are PD-L1 negative and currently ineligible for such treatments.